Respiratory failure & ventilation
Angiotensin II treatment is associated with improved oxygenation in acute respiratory distress syndrome (ARDS) patients with refractory vasodilatory shock
Primary result · P:FResult — go to the resultBaseline-adjusted difference + 98.4 mmHg 95% CI 35.2–161.5Authors' conclusion
In post-hoc analysis of the ATHOS-3 trial, angiotensin-II was associated with improved oxygenation versus placebo among patients with ARDS and catecholamine-refractory vasodilatory shock.
Study context
- Population
- Patients meeting modified Berlin ARDS criteria at enrollment with catecholamine-refractory vasodilatory shock (ATHOS-3 trial)
- Participants
- 81 patients
- Comparison
- Angiotensin II vs placebo
- Angiotensin-IIn = 34
- Placebon = 47reference
- Primary endpoint
- PaO2/FiO2 ratio (P:F) adjusted for baseline P:F
- Follow-up
- 48 h
Methodological detailsplacebo-controlled
- Placebo-controlled
Primary result
P:F · hour-48
Baseline-adjusted difference
+ 98.4 mmHg
95% CI 35.2–161.5
P = 0.0028
By group
As reported in the abstract
Secondary outcomes
| Outcome | Angiotensin-II | Placebo | Absolute risk-difference (95% CI) | P value | |
|---|---|---|---|---|---|
| Sustained hemodynamic response · hour-3 | 64.7% | 36.2% | 28.5% (6.5–47.0%) | P = 0.0120 | |
| −200204060Difference (linear scale) |
Alive and ventilator-free · day-7
Mortality · Day-28
| Outcome | Angiotensin-II | Placebo | Baseline-adjusted difference (cmH2O/mmHg) (95% CI) | P value |
|---|---|---|---|---|
| Oxygenation index change · hour-48 | - 6.0 cmH2O/mmHg | - 0.4 cmH2O/mmHg | −4.8 (- 8.6 to - 1.1) | P = 0.0273 |
PEEP, minute ventilation, ventilatory ratio
- No difference
Original publication
Angiotensin II treatment is associated with improved oxygenation in ARDS patients with refractory vasodilatory shock. Ann Intensive Care. Published 16 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →